Summary: At its Investor Day on October 1, Harmony Biosciences presented a pipeline update, highlighting progress in its sleep disorder treatments. New data from the orexin-2 agonist BP1.15205 showed potential best-in-class potency, while long-term extension data for pitolisant … [Read more...]
Harmony Advances Pitolisant High-Dose Development Program
Summary: Harmony Biosciences reported strong second-quarter results and advancements in its pitolisant high-dose (HD) development program, aiming for a PDUFA date in 2028. The company highlighted revenue growth driven by Wakix and continued progress across its sleep/wake disorder … [Read more...]
Harmony Secures Rights to Develop Bioprojet’s Orexin-2 Agonist
Summary: Harmony Biosciences has secured an unique license from Bioprojet to establish, manufacture, and commercialize TPM-1116, an oral orexin-2 receptor agonist, in the United States and Latin The united states. This drug, aimed at dealing with narcolepsy and other rest … [Read more...]